(Q38005226)

26 August 2017

title

Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections (English)

1 reference

invasive fungal infections

26 August 2017

1 reference

1 reference

2

1 reference

26 August 2017

Joanne Livermore

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

25 April 2012

1 reference

Expert Opinion on Drug Metabolism & Toxicology

26 August 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

759-765

1 reference

Therapy for fungal diseases: opportunities and priorities

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

Population pharmacokinetics of voriconazole in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.683859

10.1517/17425255.2012.683859

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference